Status:

UNKNOWN

KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs

Lead Sponsor:

IRCCS National Neurological Institute "C. Mondino" Foundation

Conditions:

Chronic Migraine, Headache

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Our protocol, named "KETOMIGRAINE", is based on the prescription of a Ketogenic Diet (KD) to twenty subjects with diagnosis of Chronic Migraine (CM), resistant to oral preventive treatments and non-re...

Detailed Description

The duration of the trial for individual participants is approximately 10 months, divided as follows: 1 month of baseline + 3 months of KD + 3 months of TD+ 3 months of follow-up. The protocol includ...

Eligibility Criteria

Inclusion

  • Age: 18-65 years old
  • Chronic migraine, diagnosed according to ICHD-3 criteria.
  • Patients with resistant form of migraine defined as: persistence of 8 days of headache per month; therapeutic failure (after therapeutic treatment of adequate dose and duration) or contraindication of 3 classes of drugs with validated evidence of efficacy in the prevention of migraine.
  • Non-responder (absence of reduction of MIDAS score of at least 50% after at least 3 months of treatment) to at least one anti-CGRP monoclonal antibody
  • Absence of prophylactic therapies for migraine or prophylaxis therapy with a single drug taken at a stable dose for at least two months
  • BMI \> 16.5 kg/m2 and \< 35 kg/m2
  • Hypothesized compliance in filling the headache diary and following the prescribed diet

Exclusion

  • Kidney failure
  • Liver failure
  • Heart failure
  • Recent heart attack
  • Pancreatitis
  • Alcoholism
  • Severe osteoporosis
  • Other neurological disorders, including other forms of primary headache, except sporadic episodic tension-type headache
  • Diabetes Mellitus
  • Severe lipid metabolism disorders
  • Women of childbearing age without active contraception
  • Pregnancy or breastfeeding
  • Psychiatric disorders that the clinician thinks may interfere with patient compliance / eating disorders
  • Other anomalies considered significant in preliminary examinations (blood tests and EKG)

Key Trial Info

Start Date :

January 14 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05313503

Start Date

January 14 2022

End Date

November 30 2023

Last Update

April 6 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Headache Science Center

Pavia, Italy, 27100